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 Introduction 
 Despite the development of more effective chemother-
apy and the refinement of surgical techniques, ovarian 
cancer remains the number one cause of death from gy-
necological cancer in the western world  [1] . Patients with 
relapsed or progressive epithelial ovarian cancer (EOC) 
are treated with agents such as topotecan, taxanes (pacli-
taxel, docetaxel, etc.), etoposide, liposomal doxorubicin, 
gemcitabine, or vinorelbine, or they are rechallenged 
with platinum-based therapy, all of which yield response 
rates of 10–30%  [2] . 5-Fluorouracil (5-FU) had an impor-
tant role in the treatment of EOC prior to the appearance 
of the new drugs, with a response rate of 5–23%  [3–7] . 
Capecitabine is an oral prodrug of 5-FU which is con-
verted at the tumor site to its active form by thymidine 
phosphorylase, an enzyme found in higher concentra-
tions in tumor compared to normal tissues  [8] , adding a 
targeting quality to the drug which becomes active main-
ly in the tumor bed. Docetaxel, a chemotherapy known 
to be active in EOC by itself, induces upregulation of thy-
midine phosphorylase within the first 10 days of admin-
istration  [9, 10] . Thymidine phosphorylase has a promi-
nent role in the therapeutic index of capecitabine, and 
upregulation of the enzyme by docetaxel could result in 
increased activity in the tumor with limited increase in 
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 Abstract 
 Objectives: To evaluate the safety and efficacy of weekly 
docetaxel with capecitabine in patients with recurrent/per-
sistent epithelial ovarian cancer (EOC).  Patients and Meth-
ods: Women treated for recurrent/persistent EOC in our 
 department (January 2004 through December 2005) were 
recruited into this feasibility study. They received 35 mg/m 2 
docetaxel on days 1 and 8 and 1,000 mg/m 2 capecitabine 
twice daily on days 1–14 in a 21-day cycle.  Results: Nine pa-
tients were enrolled. The median age was 64 years (37–80). 
Time to progression ranged from 1.67 to 11.27 months: 1 had 
complete response, 3 had partial responses, 4 had stable dis-
ease and 1 had disease progression. There was no grade 3 or 
4 bone marrow toxicity. Nonhematological toxicity included 
partial hair loss (n = 4), fatigue (n = 7), hand and foot syn-
drome (n = 2), diarrhea (n = 5) and fluid retention syndrome 
(n = 1).  Conclusion: There was good antitumor activity but 
frequent moderate-to-severe nonhematological toxicities 
when weekly docetaxel and capecitabine were used as sec-
ond-line therapy for recurrent EOC. Further investigation of 
this combination is warranted. 
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systemic toxicity. Docetaxel, an active drug in ovarian 
cancer with reduced myelosuppression in a weekly low-
dose administration, combined with daily capecitabine 
and potentiated by upregulation of thymidine phosphor-
ylase by docetaxel, are expected to be feasible and more 
effective. Finding the appropriate dose and schedule to 
maximize the therapeutic index is very challenging.
 Several small phase II studies of capecitabine in heav-
ily pretreated EOC patients reported response rates of 5–
29% and a median time to progression (TTP) of 3.7 
months. The most common side effects were hand and 
foot syndrome, nausea and vomiting, diarrhea, and mild 
myelotoxicity  [11–15] . Docetaxel in recurrent EOC 
showed response rates of 23–40%  [16–18] . The conven-
tional every-3-week administration resulted in grade 3/4 
neutropenia in more than 90% of the patients, and fatigue 
was also a frequent side effect. In breast cancer patients, 
weekly administration of docetaxel markedly reduced 
the severity of myelosuppression and fatigue, with a dose 
of 35–40 mg/m 2 having been found to be feasible and ac-
tive  [19] .
 Docetaxel and capecitabine (every 3 weeks) comprised 
the first chemotherapeutic combination to show a sig-
nificant survival advantage over single-agent therapy in 
metastatic breast cancer  [20] , although at the expense of 
excessive toxicity. Later on, phase II studies of patients 
with advanced non-small cell lung cancer evaluated 
weekly docetaxel 36 mg/m 2 on days 1 and 8 and capecita-
bine 1,000 mg/m 2 twice daily for 2 weeks  [21, 22] . The 
median duration of response was 6.2 months with a me-
dian overall survival of 17.8 months. The main side ef-
fects were hand and foot syndrome, diarrhea, nausea and 
vomiting with mild myelotoxicity  [21] . Challenged by the 
idea of weekly docetaxel modulating capecitabine to a 
synergistic effect, several small studies in breast, lung and 
other cancers  [23–26] were conducted and the results 
showed antitumor activity and moderate toxicity. The 
optimal dose and schedule could not yet be established. 
This combination of weekly docetaxel and capecitabine 
has not been evaluated in ovarian cancer, a disease sensi-
tive to both drugs.
 Our hypothesis is that the two active drugs with the 
potentiation of capecitabine by docetaxel and reduced 
docetaxel toxicity in a weekly administration might be a 
very active and feasible combination when given in the 
right schedule and doses. Since docetaxel induces upreg-
ulation of thymidine phosphorylase within the first 10 
days of administration  [9, 10] , the women were given 
docetaxel on days 1 and 8. Capecitabine was adminis-
tered on days 1–14 in order to take advantage of the en-
zyme’s upregulation. We conducted this feasibility study 
in patients with EOC who had been previously treated 
with paclitaxel and carboplatin, to assess the efficacy and 
safety of this regimen.
 Materials and Methods 
 From January 2004 through December 2005, 9 patients with 
recurrent or persistent EOC after one line of paclitaxel and car-
boplatin chemotherapy were enrolled into the study. They all had 
measurable disease as defined by bidimensional measurements 
(physical examination or radiologic techniques) or CA 125 abnor-
malities. The institutional review board approved the protocol, 
and informed consent   was obtained from all patients. Intravenous 
docetaxel was administered at a dose of 35 mg/m2 on days 1 and 
8 and oral capecitabine at a dose of 1,000 mg/m 2 twice daily on 
days 1–14 every 21 days. Response was assessed by physical ex-
amination and CA 125 levels after each cycle of chemotherapy, 
and a computerized tomographic scan was performed every 3 cy-
cles. Complete response (CR) was defined as disappearance of all 
tumor as evidenced by normalization of the serum CA 125 level, 
if initially elevated, and disappearance of all measurable lesions 
for at least one cycle of therapy or 4 weeks. A partial response (PR) 
was defined as a 50% or greater decrease in the products of the 
diameters of all measured lesions or a 50% or greater decrease in 
the serum CA 125 level compared with the pretreatment value 
that persisted for at least one cycle of therapy or 4 weeks, with no 
increase in the size of any lesion and with no evidence of new le-
sions. Disease progression (DP) was defined as any increase of 
25% or more in the sum of the products of the diameters of any 
measurable lesion or in the estimated size of any nonmeasurable 
lesion, the appearance of an unequivocal new lesion, or a 100% 
increase in the serum CA 125 values. All other conditions were 
defined as stable disease (SD). Therapy was discontinued due to 
DP, intolerable toxicity or patient refusal. Platinum-sensitive dis-
ease was defined as disease recurrence after 6 or more months 
from completion of primary paclitaxel and carboplatin chemo-
therapy. Platinum-resistant disease was defined as recurrence af-
ter less than 6 months. TTP was evaluated from the first day of 
treatment until the first evidence of DP.
 Results 
 Nine patients were enrolled. Their characteristics are 
summarized in  table 1 . Their pretreatment Eastern Co-
operative Oncology   Group performance status ranged 
from 0 to 1, and their median age was 64 years (range 
37–80). Eight patients were initially diagnosed with ad-
vanced stage (III or IV) disease. Only 1 patient was ini-
tially diagnosed with early disease, stage 1C. Seven pa-
tients had platinum-sensitive and 2 had platinum-resis-
tant disease. A median of 5 cycles (range 1.33–12.2) was 
administered. One patient had CR, 3 patients had PR, 4 
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patients achieved SD and 1 patient had DP while on treat-
ment. TTP ranged from 1.67 to 11.27 months (more than 
6 months in 6 of the 9 patients).
 There was no grade 3 or 4 bone marrow toxicity. The 
various adverse events are presented in  table 2 . Treatment 
was discontinued in 3 patients after 2–4 treatment cycles. 
Two women suffered from grade 3 diarrhea and fatigue 
requiring repeat hospitalization, intravenous fluid ad-
ministration, dose reduction and treatment discontinua-
tion, and 1 patient developed severe fluid retention syn-
drome.
 Discussion 
 Our feasibility study of weekly docetaxel and capecit-
abine showed good antitumor response with modest to 
severe nonhematological toxicity. Previous studies in 
breast  [20] and non-small cell lung cancer  [21–26] showed 
that combining capecitabine with docetaxel improves 
therapeutic response. Furthermore, this regimen was the 
only combination that showed a survival advantage over 
single-agent treatment in breast cancer patients  [20] , 
probably related to the synergistic antitumor effect of 
both drugs via the upregulation of thymidine phosphor-
ylase by docetaxel  [9, 10] .
 In light of these data together with the known baseline 
activity of 5-FU in ovarian cancer, we were intrigued to 
evaluate the activity of capecitabine and docetaxel in pa-
tients with EOC. Docetaxel as monotherapy was shown 
to be active in platinum-sensitve and refractory recurrent 
EOC  [16–18] . Single-agent capecitabine on the other hand 
was found to have only modest activity in recurrent EOC. 
In refractory and in heavily pretreated patients response 
rates of 8–9% were achieved  [14, 15] . In patients with plat-
inum-sensitive EOC recurring 6–12 months after com-
pletion of primary chemotherapy, a Gynecologic Oncol-
ogy Group study achieved only 8% response rate  [27] with 
median TTP of 3.9 months. Another phase II study  [11] 
on a mixed population of platinum-sensitive and plati-
num-resistant EOC patients showed 29% response rate 
though with a similar median progression-free survival 
of 3.7 months.
 Our feasibility study on a small number of patients 
demonstrated that the combination of weekly docetaxel 

















1 50 IIIc serous sensitive 15 0 2.2 DP 1.67
2 76 IV serous resistant 0 0 6.5 SD 5.17
3 37 IIIc serous sensitive 11 1 12.2 PR 9.50
4 69 IIIc serous sensitive 7 0 4.7 SD 4.60
5 63 IIIc serous resistant 5 1 6 SD 5.00
6 72 Ic endometrioid sensitive 31 0 5.3 CR 11.27
7 80 IV serous sensitive 8 1 1.33 SD 6.07
8 58 IIIc serous sensitive 8 0 6.8 PR 7.70
9 55 IIIc serous sensitive 7 1 2.6 PR 2.93
DFI = Disease-free interval (time from completion of primary chemotherapy to recurrence); ECOG PS = 
Eastern Cooperative Oncology Group performance status; Resp = response.
Table 2. Toxicity
Frequency of grade of severity 1







Nausea and vomiting 2
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and capecitabine is active in recurrent EOC, with CR and 
PR having been observed in 4 patients, and the achieve-
ment of SD in 4 additional patients. TTP was relatively 
long, i.e. more than 6 months in 6 of the 9 patients. These 
results can be explained by the fact that most of our pa-
tients (7/9) had platinum-sensitive disease, ranging from 
7 to 31 months ( table 1 ). However, in view of the low re-
sponse rate achieved even in platinum-sensitive patients 
using single-agent capecitabine, we believe that our en-
couraging results can be related to the combined treat-
ment and to the specific administration schedule.
 Since a regimen of capecitabine and docetaxel given 
every 3 weeks in breast cancer patients had resulted in 
severe toxicity  [20] , we chose to reduce the dose of cape-
citabine from 2,500 to 2,000 mg/m 2 /day and to adminis-
ter docetaxel in a weekly low-dose manner  [19, 28] . Un-
like the once every 3 weeks schedule of docetaxel admin-
istration, which was associated with dose-limiting 
myelosuppression and fatigue  [18, 29] , the weekly sched-
ule of 35 mg/m 2 in our study resulted in only mild hema-
tological toxicity and moderate fatigue. The capecitabine 
dose of 1,000 mg/m 2 b.i.d. resulted in a low rate of hand 
and foot syndrome. Two of the 9 study patients, however, 
suffered from grade 3 diarrhea and required repeat hos-
pitalization, intravenous fluid administration, dose re-
duction and treatment discontinuation, and 1 patient de-
veloped severe fluid retention syndrome. This relatively 
high rate of severe side effects led us to reconsider the 
doses of the two drugs. We are now planning a phase II 
study with a capecitabine dose of 650 mg/m 2 twice a day 
as was previously suggested by Nadella et al.  [10] with the 
same dose and schedule of docetaxel in platinum-resis-
tant EOC patients.
 Four of our 9 patients exhibited a therapeutic response 
(1 CR and 3 PR), 3 other patients achieved SD and most 
had no DP for more than 6 months. These favorable re-
sponses, albeit with substantial toxicity, might indicate 
clinical synergism or capecitabine potentiation by doce-
taxel.
 The standard of care in platinum-sensitive recurrent 
EOC is a doublet of platinum combined with paclitaxel, 
docetaxel, gemcitabine or Caelyx or single-agent topote-
can. In platinum-resistant patients usually each of these 
drugs is used although with disappointing results. Our 
current modest experience encourages us to recommend 
continued interest in the use of the combination of 
docetaxel and capecitabine for recurrent EOC in a setting 
of a larger clinical trial.
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